Tracking patient response to DMARD therapy has the potential to improve remission, but multiple barriers must be overcome ...

Clinical stage biopharma Kezar Life Sciences is discontinuing its lupus nephritis (LN) clinical programme following the death ...

Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...

Thousands of passionate people with lupus and those who care about the cause will join together Saturday, October 19 at the ...

The research has been published in the International Journal of Clinical Biochemistry and Research ... Conditions such as ...

Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed ...

On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active ...

In spite of considerable achievements, treatment of established lupus is a difficult task. Complete remission of mild disease with mucocutaneus or joint disease remains a challenge with a ...

Conversely, the PALIZADE Phase 2b clinical trial for zetomipzomib in patients with active lupus nephritis (LN) will be discontinued. The decision follows an IDMC recommendation after the ...

Cambridge, Massachusetts Thursday, October 17, 2024, 17:00 Hrs [IST] ...

Conversely, the PALIZADE Phase 2b clinical trial for zetomipzomib in patients with active lupus nephritis (LN) will be discontinued. The decision follows an IDMC recommendation after the occurrence of ...

The regulator's decision came after the company paused the study in September to review safety data following the deaths of ...